Keyphrases
Advanced Hepatocellular Carcinoma
100%
Response to Therapy
100%
Circulating Tumor DNA (ctDNA)
100%
Biomarkers of Response
100%
Nivolumab
100%
Hepatocellular Carcinoma Patients
50%
Progression-free Survival
50%
Overall Survival
33%
Clinical Prognosis
16%
Tumor Protein p53 (TP53)
16%
Log-rank Test
16%
Median Overall Survival
16%
Hepatocellular Carcinoma
16%
Breast Cancer Susceptibility Gene 1 (BRCA1)
16%
Treatment Selection
16%
Median Progression-free Survival
16%
Survival Prediction
16%
Cox Model
16%
Diagnosis Treatment
16%
Commercially Available
16%
CTNNB1
16%
Predictive Tool
16%
Long Progression-free Survival
16%
DNA Expression
16%
PIK3CA
16%
Progression Prediction
16%
Prognostic Tool
16%
Non-invasive Biomarkers
16%
CCND1 Amplification
16%
DNA Profiling
16%
PIK3CA Amplification
16%
Genomic Testing
16%
Medicine and Dentistry
Biological Marker
100%
Hepatocellular Carcinoma
100%
Circulating Tumor DNA
100%
Nivolumab
100%
Progression Free Survival
66%
Overall Survival
50%
Log Rank Test
16%
Survival Time
16%
Proportional Hazards Model
16%
BRCA1
16%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Biological Marker
100%
Circulating Tumor DNA
100%
Nivolumab
100%
Progression Free Survival
66%
Overall Survival
50%
Survival Time
16%